Intercept Pharmaceuticals

Intercept Pharmaceuticals Inc is owned by Genextra SpA that is focused on the development of small-molecule drugs for the treatment of chronic liver and metabolic diseases.The company is headquartered in New York City.In July 2022, ADVANZ PHARMA Corp. Limited acquired a majority of Intercept Pharmaceuticals Inc’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S..In May 2006, Genextra acquired a majority interest in Intercept Pharmaceuticals.In August 2020, Intercept Pharmaceuticals Inc announced that it has entered into privately negotiated agreements to exchange an aggregate of $306.5 million principal amount of 2023 Notes and an aggregate of $114.7 million principal amount of 2026 Notes for a newly issued series of Convertible Senior Secured Notes due 2026.In May 2019, the company announced that it had commenced an underwritten public offering to sell, subject to market and other conditions, up to $200 million of its common stock. In co